ghk-cu tolerance desensitization antibody formation long-term use Copper Peptide Regeneration Review (2018) — Research Summary The Peptides You Don't Actually
Description
In Belgium, the prevalence of analgesic nephropathy was 18%, whereas the European Dialysis and Transport Association registered a prevalence of 12% (Elseviers & De Broe, 1988)
not FDA-approved for any indication
Clinical trials typically start at 1mg or 2mg weekly
Bannister K, Dickenson AH
